 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 2 | 4 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 7 | 12 | | 2008 | 3 | 4 | 7 | | 2009 | 3 | 7 | 10 | | 2010 | 2 | 2 | 4 | | 2011 | 3 | 7 | 10 | | 2012 | 6 | 13 | 19 | | 2013 | 8 | 10 | 18 | | 2014 | 12 | 9 | 21 | | 2015 | 11 | 11 | 22 | | 2016 | 8 | 2 | 10 | | 2017 | 9 | 7 | 16 | | 2018 | 8 | 4 | 12 | | 2019 | 6 | 10 | 16 | | 2020 | 2 | 6 | 8 | | 2021 | 8 | 7 | 15 | | 2022 | 0 | 10 | 10 | | 2023 | 2 | 13 | 15 | | 2024 | 11 | 12 | 23 | | 2025 | 16 | 9 | 25 | | 2026 | 8 | 5 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Brown KK, Koucký V, Weinman JP, Simmons J, Dumistracel M, Jantzen F, Gahlemann M, Griese M. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. Pediatr Pulmonol. 2026 Jun; 61(6):e71707.
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Dixon BP, Bomback AS, Rich C, Hakimi Z, Huang M, Gordon K, Wojciechowski P, Margas W, Chang R, Duh MS, Caravaca-Fontán F, Fakhouri F. Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. Adv Ther. 2026 Aug; 43(8):3385-3402.
-
Signoretti C, Matsumura S, Doja J, Fatehi S, Williams C, D'silva M, Cendali F, Dzieciatkowska M, D'Alessandro A, Lanier GM, Gupte SA. VEGFR-2 blocker induces pulmonary vascular disease in rats with CRISPR-edited human non-deficient G6PD polymorphism: role of 3D genomic modifications and DNA methylation. Br J Pharmacol. 2026 Aug; 183(16):4675-4697.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
-
Van Braeckel E, Braun AT, Simmonds NJ, Barry PJ, Davies JC, Egan ME, Lapey A, Mall MA, McKone EF, Peckham D, Proesmans M, Ramsey B, Santamaria SV, Smith D, Taylor-Cousar JL, Tullis E, De Wachter E, Withers N, Ahluwalia N, Conner S, Jennings M, Lou Y, Weinstock TG, Keating D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2026 Jul; 25(4):682-688.
-
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS. Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. J Cyst Fibros. 2026 May; 25(3):489-494.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|